Navigation Links
Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
Date:8/19/2007

ment of diarrhea caused by Cryptosporidium parvum or Giardia lamblia in patients 1 year of age and older. Alinia has not been shown to be superior to placebo for the treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients. The most common adverse events reported by patients receiving Alinia have been abdominal pain, diarrhea, headache and nausea. In controlled trials, the frequency of these events has been similar to patients receiving a placebo.


'/>"/>
SOURCE Romark Laboratories, L.C.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Malvern initiates European user group meetings for chemical imaging
2. Genetic Analysis Systems Enter the Clinical Mainstream
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation (Nasdaq: ... successful testing of a novel integrated light source architecture ... engine design raises the bar on imaging speed and ... OCT light sources. This approach to optical engines ...
(Date:12/4/2009)... Neal Shore and E. David Crawford presented results for ... secondary end points of biochemical recurrence rate in a ... injection) or monthly leuprolide in prostate cancer patients during ... who received FIRMAGON 240/80 mg/month had a recurrence rate ...
(Date:12/3/2009)... NEW YORK, Dec. 3 Guidepoint Global, LLC , ... their Sleep Apnea Tracker, a monthly longitudinal data release that ... Sleep Apnea market. ,, The Sleep Apnea Tracker captures ... sold in the United States from 15 different equipment providers ...
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2ZyGEM Releases Data Confirming Its prepGEM 28R 29 Bacteria Kit Is a Simple Universal Method for Extracting DNA from Different Bacteria Species 51198 1ZyGEM Releases Data Confirming Its prepGEM 28R 29 Bacteria Kit Is a Simple Universal Method for Extracting DNA from Different Bacteria Species 51198 2ZyGEM Releases Data Confirming Its prepGEM 28R 29 Bacteria Kit Is a Simple Universal Method for Extracting DNA from Different Bacteria Species 51198 3ZyGEM Releases Data Confirming Its prepGEM 28R 29 Bacteria Kit Is a Simple Universal Method for Extracting DNA from Different Bacteria Species 51198 4Life Spine 28R 29 Announces FDA Clearance of FS3 28TM 29 Minimally Invasive Spinal System 51196 1Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat P 12956 1Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat P 12956 2Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat P 12956 3
... medical and economic advantages of nifedipine,GITS therapy ... 28, 2007 – Two recently,published articles in ... that the use of the long-acting calcium ... additional,benefits beyond its blood pressure lowing effect. ...
... shows orally-delivered GLP-1 is able to stimulate ... --,Emisphere Technologies, Inc. reported today results of ... Christoph,Beglinger, M.D. Division of Gastroenterology and Hepatology,University ... of,the study with glucagon-like peptide-1 (7-36 amide) ...
Other Medicine Technology:Calcium Channel Blocker Adalat GITS Offer Additional Benefits 2Calcium Channel Blocker Adalat GITS Offer Additional Benefits 3Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 2Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 3Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 4Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 5
(Date:12/6/2009)... -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Phase 2b 003-A1 study, known as the 003 ... pre-treated relapsed and refractory multiple myeloma patients. These ... Symposium at the 51st annual meeting of the ... Enrollment in this trial is complete (n=269), and ...
(Date:12/6/2009)... study provides welcome news for patients with a common ... The condition is estimated to impact 62,000 Canadians and ... clot forms in a vein and restricts the flow ... the clot may detach from its point of origin ... a potentially fatal condition known as a pulmonary embolism. ...
(Date:12/6/2009)... of Belluck & Fox, LLP says dangerous substances such as asbestos ... ... New York, NY (PRWEB) December 6, 2009 -- As ... be alert to reports of recalls due to lead paint or ... to 230,000 children visit hospital emergency rooms each year due to ...
(Date:12/5/2009)... Cuts for a Cause ,, Why: ... other terminal illnesses affecting children. All proceeds from each hair ... Hospital. Guests will enjoy complimentary beverages and hors d,oeuvres, provided ... Falls Church for all guests. Hoa Lai, a DJ known ...
(Date:12/5/2009)... Dec. 5 Leukemia and myeloproliferative disorders are ... today at the 51st Annual Meeting of the ... options and improved diagnostic methods for patients suffering ... acute lymphoblastic leukemia, and myelofibrosis that are based ...
Breaking Medicine News(10 mins):Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9
... UNICEF have renewed their international partnership for children for another ... on HIV/AIDS 'Unite For Children, Unite Against AIDS'. ... children to enjoy healthy recreation and promote girls' education in ... the agreement. ,UNICEF's regional office for South Asia ...
... body that is responsible for approving NHS treatments has ... blocked the usage of an anti-cancer drug. ... treated with the drug Alimta, whose scientific name ... National Institute for Health and Clinical Excellence (NICE). ...
... Post, the department of health of Washington, D.C.//, on Tuesday is ... between 14years and 84years, to a test, to ... launching of the campaign, to be named “Come Together D.C. ... HIV Testing Day. ,Gregg Pane, the director of the. ...
... It has been reported that towards the end of last ... transplant//. ,Surgeons at Sydney's Royal Prince Alfred Hospital ... Myles of Cowra in central-eastern New South Wales. Leanne Myles ... failure of her liver, kidneys, and pancreas. ,She ...
... Mice lacking a gene for normal immune functioning found ... attacks //liver and spleen - a new study finds. ... a pathogen called Leishmania donovani, affects certain internal organs. ... quite often affected by this infectious disease through the ...
... department today advised people to take precautionary measures in view ... and jaundice during summer. // ,The people have ... minutes and wash raw vegetables and fruit thoroughly before eating, ... has also advised people to wash hands with soap after ...
Other Medicine News:Health News:Lack of STAT1 -an Immune Protein, Pack Liver Infection Cure 2Health News:Lack of STAT1 -an Immune Protein, Pack Liver Infection Cure 3
Silicone Foley Catheters 3-Way...
Midstream Catch Kits...
... Pediatric BladderScan® is the ... Ultrasound's trusted family of ... healthcare providers to measure ... noninvasively, this easy-to-use, handheld ...
... BladderScan BVM 6500 enables ... to determine UEBW (ultrasound ... bladder volume using 3-dimensional ... 6500 was designed to ...
Medicine Products: